N Nanobiotix
N
Cerrado
31.4 -0.06
Resumen
Variación precio
24h
Mínimo
30.7
Máximo
31.56
Ingresos | -19M |
|---|---|
Ventas | 3M |
Margen de beneficios | -618.236 |
Empleados | 100 |
EBITDA | -13M |
Próximas Ganancias | 29 sept 2026 |
|---|
Capitalización Mercado | 1.7B |
|---|---|
Apertura anterior | 31.46 |
Cierre anterior | 31.4 |
Nanobiotix Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Nanobiotix previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.